

Corrigendum: "Cancer cell gene expression modulated from plasma membrane integrin αvβ3 by thyroid hormone and nanoparticulate tetrac"

Paul J. Davis^{1,2*}, Gennadi V. Glinsky³, Hung-Yun Lin⁴, John T. Leith⁵, Aleck Hercbergs⁶, Heng-Yuan Tang², Osnat Ashur-Fabian^{7,8}, Sandra Incerpi⁹ and Shaker A. Mousa²

¹ Department of Medicine, Albany Medical College, Albany, NY, USA, ² Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA, ³ Stanford University, Palo Alto, CA, USA, ⁴ Taipei Medical University, Taipei, Taiwan, ⁵ Rhode Island Nuclear Science Center, Narragansett, RI, USA, ⁶ Cleveland Clinic, Cleveland, OH, USA, ⁷ Hematology Institute and Blood Bank, Meir Medical Center, Kfar-Saba, Israel, ⁸ Department of Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁹ Department of Sciences, University Roma Tre, Rome, Italy

Keywords: integrin, thyroid hormone, tetraiodothyroacetic acid (tetrac), nano particle, gene expression, corrigendum

A corrigendum on

OPEN ACCESS

Edited by:

Wen Zhou, Columbia University, USA

Reviewed by: Jean-Yves Scoazec, Université Lyon 1, France

*Correspondence:

Paul J. Davis pdavis.ordwayst@gmail.com

Specialty section:

This article was submitted to Cancer Endocrinology, a section of the journal Frontiers in Endocrinology

> **Received:** 27 May 2015 **Accepted:** 27 May 2015 **Published:** 09 June 2015

Citation:

Davis PJ, Glinsky GV, Lin H-Y, Leith JT, Hercbergs A, Tang H-Y, Ashur-Fabian O, Incerpi S and Mousa SA (2015) Corrigendum: "Cancer cell gene expression modulated from plasma membrane integrin αvβ3 by thyroid hormone and nanoparticulate tetrac". Front. Endocrinol. 6:98. doi: 10.3389/fendo.2015.00098 Cancer cell gene expression modulated from plasma membrane integrin $\alpha v\beta 3$ by thyroid hormone and nanoparticulate tetrac

by Davis PJ, Glinsky GV, Lin H-Y, Leith JT, Hercbergs A, Tang H-Y, et al. Front Endocrinol (2015) 5:240. doi: 10.3389/fendo.2014.00240

In Table 2, the section designated "Disabling of cell survival pathway gene expression," line 5 incorrectly states "...pro-apoptotic miR-21"; the correct statement is "...pro-apoptotic miR-15A." The issue is correctly discussed in the body of the published text, p. 2, right column, paragraph 4.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2015 Davis, Glinsky, Lin, Leith, Hercbergs, Tang, Ashur-Fabian, Incerpi and Mousa. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.